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ess: djc_69_98@yahoo.Summary In pleural infection, it has been recommended that Gram stain and
cultures should be obtained on a routine basis. However, this recommendation has
not been tested prospectively. We evaluated the yield of microbiological studies in
259 patients with parapneumonic pleural effusion. Microbiological studies were
positive on the pleural fluid of 50 patients (19.3%). In 48 of the 50 patients with
positive microbiological results (96%), the need for pleural drainage was correctly
predicted by pleural fluid parameters. There were no differences in hospital stay
(9.572.5 days versus 9.973.2 days, P ¼ 0:68) or in mortality (2 deaths in each
group, P ¼ 0:58) between the group of patients in which antibiotic treatment was
changed according to microbiological results and the group of patients in which it is
not. In conclusion, this study demonstrates that, at least in our institution, routine
microbial investigation of pleural fluid adds very little to the standard management
of parapneumonic effusions.
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Pleural effusions develop in up to 44% of patients
with community-acquired pneumonia (CAP).1 Cur-
rent guidelines for the management of pneumoniad.
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Routine use of pleural fluid cultures 2049and parapneumonic effusions do not recommend
routine sputum culture and Gram’s stain but
generally agree in recommending pleural fluid
microbiological studies to direct antibiotic treat-
ment and need for pleural drainage.2–4 Most
clinicians obtain Gram stains and cultures of
pleural fluid in the evaluation of their patients
with parapneumonic pleural effusions (PPEs). How-
ever, the utility of pleural fluid stains and cultures
as a diagnostic tool has not been prospec-
tively evaluated. To our knowledge, there are no
studies assessing the impact of microbiological
studies on treatment decisions and patient
outcomes.
We conducted a prospective study of patients
with PPE in order to assess the usefulness of the
pleural fluid stain and culture in guiding the initial
antibiotic therapy and need for pleural drainage.
We hypothesized that pleural fluid smears and
cultures would be positive in only a minority of
patients and would not contribute significantly to
patient management.Methods
Patients and study design
All patients diagnosed as having PPE in the
Respiratory Department between January 1995
and December 2000 were candidates for the study.
We prospectively included all patients with pleural
exudates associated with pneumonia who under-
went diagnostic thoracentesis. Patients with anti-
biotic use during the week prior to hospitalization
were excluded from this study. Patients with human
immunodeficiency virus/acquired immunodefi-
ciency syndrome (HIV/AIDS) or bronchiectasis were
also excluded.
Patients with positive microbiological cultures in
the pleural fluid in the pleural space were
separated into two groups: in one group antibiotic
therapy was changed based on culture and suscept-
ibility studies; in the other group antibiotic therapy
was not changed by decision of the attending
physicians, according to the clinical evolution of
patients.
Microbiological studies
Pleural fluid specimens were inoculated into blood
culture media at the bedside for both aerobic and
anaerobic cultures. Pleural fluid specimens were
sent immediately to the local hospital laboratory
for Gram staining.Definitions
A parapneumonic effusion is an accumulation of
exudative pleural fluid associated with an ipsilat-
eral pulmonary infection. Empyema is frank pus in
the pleural space.
Treatment of patients
All patients were treated according to current
guidelines along the study period.4,5 Pleural fluid
drainage was instituted when the pleural fluid pH
was less than 7.20, the pleural fluid LDH was higher
than 1000 IU/L (upper normal limit for serum
300 IU/L), the pleural fluid was pus, or when the
Gram stain or culture were positive. The presence
of loculations in the pleural space or empyema
served as an indication for the use of thrombolytic
agents. If the patients deteriorated despite these
treatments, they were referred for thoracoscopy.
Measurements
The following end points were recorded: yield of
the microbiological studies among PPE, the yield of
Gram stain as compared with cultures, the useful-
ness of pleural fluid parameters to predict need of
pleural drainage and the impact of microbiological
studies on mortality and hospital in-stay.
Statistical analysis
Statistical analysis was performed using computer
software (SPSS for Windows, version 10.0; SPSS
Inc., Chicago, IL). Results were expressed as
mean7SD unless otherwise stated.
The means of parameters with a normal distribu-
tion were compared using the Kolmogorov–Smirnov
test. The characteristics of the patients in the two
groups were compared using the w2-test with
Fisher’s or Yates correction for non-continuous vari-
ables, the non-parametric Mann–Whitney U-test
for continuous variables with non-normal distribu-
tion and Student’s t-test for those with normal
distribution.
Two-tailed P values of 0.05 or less were con-
sidered statistically significant.Results
During the study, 259 potentially eligible patients
with PPEs were evaluated. Microbiological studies
were positive on the pleural fluid of 50 patients
(19.3%). A detailed list of the pathogens involved is
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only 14 patients (5.4.%) and of these nine had
negative cultures (Table 2). The culture was a more
sensitive test in that it was positive in 41 patients
(15.8%) (Table 2).
In 48 of the 50 patients with positive micro-
biological results (96%), the need for pleural
drainage was correctly identified by pleural fluid
parameters (40 patients with a pH less than 7.20; 9
patients with an LDH higher than 1000 IU/L and 33
patients with pleural glucose levels lower than
60mg/dL). Sixteen patients had only one para-
meter which defined the need of pleural drainage,
30 had two and two had the three parameters. In
one of the patients in which pleural parametersTable 1 Pathogens identified in 259 cases of
parapneumonic effusions.
Microorganisms Number %
Gram-positive 21 51.2
Streptococcus pneumoniae 6 14.6
Streptococcus sp. 4 9.7
Micrococcus sp. 4 9.7
Staphilococcus aureus 3 7.3
Coagulase-negative
Staphylococcus
3 7.3
Enterococcus faecalis 1 2.4
Gram-negative 17 41.4
Escherichia coli 4 9.7
Propionibacterium sp. 4 9.7
Pseudomonas aeruginosa 3 7.3
Proteus mirabilis 2 4.9
Acinetobacter
calcoaceticus
1 2.4
Salmonella sp. 1 2.4
Haemophilus influenzae 1 2.4
Other Enterobacteriaceae 1 2.4
Anaerobes 2 4.9
Prevotella sp. 1 2.4
Lactobacillus sp. 1 2.4
Others 1 2.4
Mycoplasma pneumoniae 1 2.4
Table 2 Results of Gram stain as compared with
cultures from pleural fluid samples.
Gram stain Number (%)
Positive
culture
Negative
culture
Total
Positive 5 (1.9) 9 (3.5) 14 (5.4)
Negative 36 (13.9) 209 (80.7) 245 (94.6)
Total 41 (15.8) 218 (84.2) 259 (100)failed to predict the need of pleural drainage,
Proteus mirabilis was isolated from pleural fluid.
Although the patient did not get a chest tube, he
recovered with antibiotic treatment alone. The
other patient had pleural drainage because of a
purulent pleural fluid and did well.
Patients with positive microbiological studies
were separated into two groups: in one group
antibiotic therapy was changed based on culture
and susceptibility studies (group 1); in the other
group antibiotic therapy was not changed by
decision of the attending physicians, according to
the clinical evolution of patients (group 2).
There were no significant differences between
the two groups in terms of demographic factors or
pleural fluid parameters except for a trend toward
higher pleural volumes (as a percentage of the
entire hemithorax, subjectively visually assessed)
between patients from group 1. Patients from
group 1 were on antibiotics for a significantly
(P ¼ 0:02) longer time than patients from group 2.
One patient from group 1 with Streptococcus
pneumoniae in pleural fluid died although anti-
biotic regimen was changed according to the
antibiogram. Inadequate initial antibiotic therapy
was identified but not changed in 6 patients from
group 2 (16%) but the outcome of these patients
was good except for one patient who died on the
third day of hospitalization, before culture results
were available (which revealed Staphylococcus
aureus). There were no significant differences in
length of hospital stay or in mortality between
groups (Table 3).Discussion
The present study demonstrates the limited value
of microbiological studies as a diagnostic tool in the
initial evaluation of patients with parapneumonic
effusion. These limitations include low diagnostic
yield, low rate of rapid diagnosis (Gram stain), no
impact in therapeutic decisions, minimal additional
information to that given by biochemical para-
meters and no impact on mortality or in-hospital
stay.
The recent update of the American Thoracic
Society guidelines6 states that sputum culture and
Gram’s stain are not required for patients with CAP
but recommends obtaining pleural fluid samples for
Gram stain and culture in cases of parapneumonic
effusions; however, there are no studies which
support this recommendation. The major finding in
the present study is that among 259 patients with
parapneumonic effusion, pleural fluid studies in
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Table 3 Characteristics of the subjects in the two study groups.
Characteristics GROUP 1 GROUP 2 P
Culture-guided therapy (N ¼ 13) Empiric therapy (N ¼ 37)
Range Value Range Value
Age 20–87 64.7714.5 25–83 61.7714.6 0.53
Sex (M/F) 6/7 21/16 0.74
Empyema (Yes/No) 8/5 19/18 0.76
Volume (%) 5–90 59.1724.4 5–90 47.9727.5 0.05
Symptoms before diagnosis (days) 1–22 5.874.3 1–23 6.675.2 0.62
Fever (1C) 36–40 37.570.7 36–39 37.670.6 0.62
Leukocytes/mm3 2100–19,000 8595.374049.4 1600–19,100 9378.473933.8 0.54
Hospital in-stay (days) 5–16 9.572.5 5–21 9.973.2 0.68
Positive blood cultures (number) 3 5 0.71
Pleural fluid
pH 6.6–7.4 7.170.2 6.8–7.5 7.270.1 0.20
Glucose (mg/dL) 5–109 49.7724.9 11–121 57.1730.6 0.44
LDH (UI/L) 23–4379 681.17660.4 44–1580 532.77327.6 0.29
Leukocytes/mm3 400–8800 3565.171777.8 700–7700 3876.771756.6 0.58
Inadequate antibiotic therapy 13 6 o0.0001
Change in antibiotic therapy 13 0 o0.0001
Antibiotic days 7–26 13.375.4 7–21 11.173.3 0.02
Drainage required (number) 1–3 1.270.4 0–3 1.170.4 0.44
Fibrinolysis (%) 23.1 21.6 0.78
Thoracoscopy (number) 0–1 1 0–1 1 0.97
Thoracostomy (number) 0 0 NS
Immediate mortality (number) 2 2 0.58
Six-months mortality (number) 3 3 0.35
Follow-up (days) 8–500 225.9789.8 9–515 237.27108.2 0.74
Routine use of pleural fluid cultures 2051only 50 (19.3%) yielded a pathogen. These results
are comparable to those of Davies et al.7 who found
25% positive microbiological results, and Poe et al.8
who reported positive microbiological findings in
27% of their patients. However, patients in their
series were sicker as 47% met one or more criteria
for tube thoracostomy compared to 19% in our
series. Ferrer et al.9 found 37% positive findings,
although 54% of their patients had an empyema. In
the series of Wait et al.,10 60% of patients had a
positive pleural culture. However, these results are
limited by the small number of patients (11 and 9 in
each group, respectively). Moreover, 90% of their
patients had loculations indicating an advanced
stage. In our series, such low yields cannot be
ascribed to poor processing of the specimens or to
suboptimal laboratory techniques of smear exam-
ination and culture, since similarly handled and
processed specimens from other categories of
patients with infectious diseases show higher yields
in the same laboratory. Prior use of antibiotics as a
cause of low yield also can be ruled out since
patients with antibiotic use in the week prior to
hospitalization were excluded.
In our study Gram stain had a low diagnostic yield
and a low number of positive samples had acorresponding growth in culture. One explanation
may be the lack of investigators who were familiar
with the evaluation of Gram stains. In fact, the
yield of Gram stains has proven to be highly
dependent on a skilled investigator applying strict
criteria.11
The impact of pleural microbiological data on
therapeutic decisions was negligible. A positive
Gram stain, even in non-purulent fluid, implies an
advanced stage and suggests the need for immedi-
ate drainage.12 In our study, all but one patient
with a positive Gram stain had a pleural fluid
pH indicated the need for pleural drainage.
Twenty-nine of our patients had positive cultures
with non-purulent fluid and negative Gram
stains. In 28 out of these 29 patients (96.5%),
biochemical fluid analysis predicted need of pleural
drainage. These results confirm that, although
pleural fluid analysis is less than 100% sensitive,7,8
it can be used accurately to predict need of pleural
drainage.
In this study, Gram stains and cultures added very
little to the management of patients who received
an empirical initial antimicrobial regimen. Inade-
quate initial antibiotic therapy was identified in
11% and modified in 7% of patients. Narrowing
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as cost-saving measure and by potentially reducing
the likelihood of antibiotic resistance. However,
physicians are reluctant to use narrow antibiotic
therapy even when culture results indicate this is
appropriate.13 Several potential explanations for
this reluctance exist. Multiple pathogens may be
present in up to 50% patients with CAP.14,15
Physicians may also have been reluctant to reduce
therapy because of medical/legal concerns.
Mortality and in-hospital stays were not different
whether treatment was modified by the results of
the culture. Our in-hospital mortality rate was low
(4.6%) compared with other series16,17 and similar
to that of Davies et al.7 This confirms the conclu-
sion of a previous study in which early and
aggressive medical management for patients with
pleural infection was associated with a good out-
come.7 Other studies have found no difference in
mortality between patients with pneumonia in
whom antibiotics were changed empirically and
those who had a change in therapy guided by a
positive microbiological study in sputum or
blood.18,19 Our results are similar to others which
have shown that initial appropriate antimicrobial
treatment is the most important factor of good
outcome in patients with CAP.20,21
Our results are similar to that of Barnes et al.22
However, our study has several strengths. First,
ours is a prospective study and all patients were
consecutively managed in a similar way. Second, as
we only included patients with a final diagnosis of
parapneumonic effusion, patients with false-posi-
tive microbiological findings were not included in
our analysis.
In conclusion, this study demonstrates that, at
least in our institution, routine microbial investiga-
tion of pleural fluid adds very little to the standard
management of parapneumonic effusions. Cultures
do not identify additional patients who need chest
tube drainage. Moreover, the results of cultures do
not appear to dictate changes in antibiotic therapy.
Based on our data, we would recommend that
microbiological pleural fluid studies not to be
ordered routinely in patients with parapneumonic
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